A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.
All News
Advertisement
Advertisement
The AHA and ACC commend the focus on fruits, vegetables, and whole grains but caution against high-fat dairy and protein emphasis.
Your daily dose of the clinical news you may have missed.
New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.
Your daily dose of the clinical news you may have missed.
COVID-19 vaccination before infection significantly reduces hospitalization, critical care admissions, and preterm birth rates in pregnant individuals, study finds.
Your daily dose of the clinical news you may have missed.
.jpg?w=350&fit=crop&auto=format)
FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.
Your daily dose of the clinical news you may have missed.
The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.
Advertisement
Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.
Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.
A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.
Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.
The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.
Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
Completion of the screening pathway—not test selection alone—may define quality going forward.
Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.
Your daily dose of the clinical news you may have missed.
Advertisement
Advertisement
Advertisement